532523:BOM
Biocon Ltd
350,00 ₹
arrow_downward
-0,43%(-1,50) 1D
16 հոկ, 15:30:00 GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 532523...
Open
352,95 ₹
High
352,95 ₹
Low
348,10 ₹
Mkt. cap
568,79 մլրդ
Avg. vol.
692,61 հզր
Volume
668,34 հզր
Dividend
0,14%
Quarterly dividend
0,13 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
103,62
52-wk high
447,00 ₹
52-wk low
337,95 ₹
EPS
3,38 ₹
Shares outstanding
600,00 մլն
No. of employees
16 հզր
Open
352,95 ₹
High
352,95 ₹
Low
348,10 ₹
Mkt. cap
568,79 մլրդ
Avg. vol.
692,61 հզր
Volume
668,34 հզր
Dividend
0,14%
Quarterly dividend
0,13 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
103,62
52-wk high
447,00 ₹
52-wk low
337,95 ₹
EPS
3,38 ₹
Shares outstanding
600,00 մլն
No. of employees
16 հզր
News stories
From web sources and news partners
Simply Wall Street
·
38 րոպե առաջ
Does Stablecoin Backed Cards Change The Bull Case For Marqeta (MQ)?
Yahoo Finance
·
3 ժամ առաջ
Michael Burry Warns Stock Market Could Be Months Away From A 2000-Style Reckoning — ‘The Preconditions Seem Set For Fireworks’
Crypto Briefing
·
57 րոպե առաջ
Morgan Stanley ties S&P 500 growth to a $1.6 trillion AI spending wave
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16,4 հզր
Founded29 նոյ, 1978 թ.
HeadquartersԲանգալոր, Կառնատակա, Հնդկաստան
Sector-
Websitebiocon.com